IngredientsTurmerones are a group of related chemical compounds of the sesquiterpene class, found in turmeric (Curcuma longa), from which they derive their name, as well as other related plants such as Curcuma caesia. Curcuma longa is a plant of the Zingiberaceae family, originally from South Asia. It is a perennial tuberous plant from the genus Curcuma (Zingiberaceae) and has been widely used in foods for thousands of years.
There are multiple structural types of turmerones which differ in the number and placement of double bonds, including α-turmerone, β-turmerone (also known as curlone), and ar-turmerone, each of which consists of multiple stereoisomers.
The structures of the principal turmerones have been formally characterized in the chemical literature. The presence of two turmerones in turmeric has been demonstrated, with their structures defined as 2-methyl-6-(4-methylcyclohexa-2,4-dien-1-yl)hept-2-en-4-one (α-turmerone) and 2-methyl-6-(4-methylenecyclohex-2-en-1-yl)hept-2-en-4-one (β-turmerone). Ar-turmerone carries the IUPAC name 2-methyl-6-(4-methylphenyl)-2-hepten-4-one. Using spectroscopic methods, α-turmerone has been confirmed as (1′R, 6S)-2-methyl-6-(4-methylcyclohexa-2,4-dienyl)hept-2-en-4-one, and β-turmerone as (1′R, 6S)-2-methyl-6-(4-methylenecyclohex-2-enyl)hept-2-en-4-one.
Turmerone is a non-polar 1,4-dialkylaryl metabolite isolated as a constituent of essential oil from turmeric (Curcuma longa). The compound is also known by the synonyms (+)-(S)-ar-turmerone, (+)-Turmerone, and (+)-ar-Turmerone. The molecular formula shared by the turmerone sesquiterpenes is C15H20O. A high-speed counter-current chromatography (HSCCC) method has been developed for the preparative separation of the four major sesquiterpenoids—ar-turmerone, β-turmerone, α-turmerone, and E-α-atlantone—from the essential oil of Curcuma longa.
Turmerones (α-turmerone, β-turmerone, and ar-turmerone) are the major volatile compounds in turmeric (Curcuma longa). Aromatic tumerone (20–30%) has been reported to be the major compound present in turmeric volatile oil. However, proportions vary considerably by origin and extraction method: GC-MS of hexane extracts of turmeric rhizome has yielded very different percentages, for example ar-turmerone ranging from 2.6–70.3%, α-turmerone from trace–46.2%, and zingiberene from trace–36.8%.
Major compounds present in turmeric essential oils include ar-turmerone, α-turmerone, and β-turmerone, and the relative proportions of these terpenoids in turmeric essential oil (TEO) extracts vary depending on the rhizome's geographic origin and method of extraction. In the leaf oil, ar-turmerone (63.4%), alpha-turmerone (13.7%), and beta-turmerone (12.6%) have been identified as the major components.
The chemical constituents of turmeric volatile oil are identified using GC and GC-MS, with main components including ar-tumerone, zingiberene, turmerone, and curlone. Turmerones are present in the following preparations derived from Curcuma longa:
Turmeric has been utilized by humans for nearly 6,000 years and was historically widely used in Ayurveda medicine and traditional Asian medicine such as traditional Chinese medicine. Traditional preparations of turmeric include powdered rhizomes incorporated into pastes, decoctions, and infusions; in Ayurveda, turmeric powder is often mixed with water, milk, or oils to create pastes applied to wounds or consumed for systemic effects.
Turmeric has a long history of traditional use in the Chinese and Ayurvedic systems of medicine, particularly as an anti-inflammatory agent, and for the treatment of biliary disorders, anorexia, coryza, cough, diabetic wounds, hepatic disorders, rheumatism, and sinusitis. The powdered rhizome is used externally as an antiseptic and taken internally to cure gastritis.
In Ayurveda, turmeric is associated with purity and cleansing, and represents fertility and new beginnings, and was often used to bless objects, doorways or people. It is also a rich source of manifold active components such as the water-soluble peptide turmerin, and essential oils containing turmerone and zingiberene, which exhibit an array of pharmacological activities.
In traditional Chinese medicine, turmeric is used to cure diseases linked to abdominal pain and to improve digestion, and is often added to food preparations such as rice and beans to alleviate digestion and reduce gas and bloating. In traditional Chinese medicine, the differentiation between the primary rhizome (called the "tuber") and the secondary rhizome is retained in classification.
Historically, turmeric has been used in various traditional medicine systems, such as Ayurveda, Unani, and Traditional Chinese Medicine, for ailments ranging from inflammation and wounds to digestive disorders, and more complex diseases such as cancer and neurodegenerative conditions. C. longa is traditionally used to treat wound helminthic infections, fevers, skin eruption, conjunctivitis, cough, parasitic infections, and liver diseases.
While the historical use of turmeric as a whole herb is well-documented, it is important to note that pre-modern traditions did not isolate or identify individual turmerone compounds. Traditional use relates to the whole rhizome, its powders, pastes, and decoctions, in which turmerones contribute as part of the essential oil fraction alongside curcuminoids and other constituents.
Turmeric's chemical composition is constituted by the presence of turmeric oil, rich in oxygenated sesquiterpenoids (ar-, α-, β-turmerone, and α-atlantone), and curcuminoids (curcumin, monodemethoxycurcumin, and bisdemethoxycurcumin). Most pharmacological properties such as anti-inflammatory and antioxidant ones are primarily attributed to curcumin, whose concentration in the rhizomes ranges from 3 to 9%; however, curcumin-free extracts and preparations have also been reported biologically active on different diseases such as tumors and diabetes.
Turmeronoids (i.e., ar-, α-, and β-turmerone), the volatile bisabolane sesquiterpenes, may give an important contribution to the plethora of pharmacological activities attributed to turmeric. Non-curcuminoids such as turmerones, elemene, bisacurone, curdione, cyclocurcumin, germacrone, furanodiene, curcumol, and calebin A have been extensively studied for pharmacological activities such as anti-inflammatory, antioxidant, and anticancer activities.
Turmerones are classified as α, β, and ar-turmerone based on their chemical structures, and the different types of turmerones are distinguished by the difference in the number and location of double bonds, which promotes additional biological characteristics such as antioxidant, anti-tumor, and anti-inflammatory activities. Ar-turmerone is the fully aromatic form, bearing a 4-methylphenyl ring, which confers distinct physico-chemical and receptor-binding properties compared to α- and β-turmerone, which retain the cyclohexadienyl and methylenecyclohexenyl ring systems, respectively.
Preclinical research has identified several molecular mechanisms through which turmerones, particularly ar-turmerone, exert biological activity. These mechanisms are drawn exclusively from in vitro and animal studies; no human mechanistic data is available.
The bulk of research on turmerones is preclinical: in vitro (cell culture) and in vivo (animal). Specific clinical trials isolating turmerones as interventions, separate from whole turmeric or curcumin, are not yet established. Where human-cell studies exist (such as Caco-2 intestinal cell models), these are noted as in vitro only. The evidence strength is clearly characterized in each subsection below.
Evidence level: In vitro and animal studies only; no human clinical trials on isolated turmerones.
The most widely cited study on turmerone's neurological properties is the 2014 work by Hucklenbroich et al., published in Stem Cell Research & Therapy (PMID: 25928248). Primary fetal rat neural stem cells (NSCs) were exposed to various concentrations of ar-turmerone, after which cell proliferation and differentiation potential were assessed. In vivo, naïve rats were treated with a single intracerebroventricular injection of ar-turmerone, and proliferative activity of endogenous NSCs was assessed using noninvasive positron emission tomography (PET) imaging with the tracer [18F]-fluoro-L-thymidine ([18F]FLT), as well as ex vivo.
In vitro, ar-turmerone increased dose-dependently the number of cultured NSCs due to an increase in NSC proliferation (P < 0.01), with proliferation data supported by qPCR data for Ki-67 mRNA. In vitro as well as in vivo, ar-turmerone promoted neuronal differentiation of NSCs. In vivo, after intracerebroventricular injection of ar-turmerone, proliferating NSCs were mobilized from the subventricular zone (SVZ) and the hippocampus of adult rats, as demonstrated by both [18F]FLT-PET and histology (P < 0.05).
Both in vitro and in vivo data suggest that ar-turmerone induces NSC proliferation, and ar-turmerone thus constitutes a promising candidate to support regeneration in neurologic disease. As ar-turmerone both limits microglia activation and induces NSC proliferation, it constitutes a promising future drug candidate to support regeneration in neurologic disorders.
A more recent study (2025, PMC) investigated ar-turmerone in Alzheimer's disease models. The anti-inflammatory and cognitive-protective effects of ar-turmerone were evaluated in both in vitro and in vivo models of amyloid-β-induced neurotoxicity; primary cultured rat hippocampal neurons exposed to Aβ showed significantly increased expression of TNF-α, IFN-β, and iNOS, all of which were dose-dependently attenuated by ar-turmerone, which also suppressed Aβ-induced activation of the TLR4/NF-κB signaling axis at mRNA and protein levels. In an amyloid-β-injected mouse model, oral administration of ar-turmerone significantly improved learning and memory performance in the Morris water maze and passive avoidance tests; biochemical analyses of hippocampal tissues revealed reduced TLR4 expression and NF-κB activation, decreased acetylcholinesterase activity, and restoration of acetylcholine levels following treatment, suggesting that ar-turmerone exerts neuroprotective effects by inhibiting TLR4/NF-κB-mediated neuroinflammation and preserving cholinergic function.
Limitation: All neurological research on turmerones consists of in vitro and animal model work. No randomized controlled trials in human subjects have been conducted on isolated turmerones for any neurological indication.
Evidence level: In vitro, animal, and one comparative study with human-relevant cell lines; no large-scale human clinical trials.
A number of in vitro biological activities of turmerones have been reported, including anti-inflammatory, immunomodulatory, antiproliferative, and antifungal activities. Studies over the past decade have indicated that curcumin-free turmeric (CFT) components possess numerous biological activities including anti-inflammatory, anticancer, and antidiabetic activities.
The comparative anti-inflammatory study by Bagad et al. (2013, Advances in Pharmacological Sciences) examined curcuminoids, turmerones, and an aqueous extract of Curcuma longa against one another in an experimental setting. Methanolic extract of C. longa reduced the progression of arthritis by NF-κB inactivation; crude and refined essential oils from C. longa rhizomes showed antiarthritic activity in preclinical and clinical trials with safety; the authors suggested that the observed activities are associated with curcuminoids and constituents of turmeric oil.
Preclinical rodent work on the essential oil fraction (dominated by turmerones) has been published. Lipophilic compounds (turmerones) isolated from turmeric oil were evaluated in a streptococcal cell wall-induced rheumatoid arthritis murine model; turmeric hexane extract at doses above 28 mg/kg/day (i.p.) displayed a potent anti-inflammatory response accompanied by high murine hepatotoxicity and mortality at 56 mg/kg/day; conversely, no toxicity signs or mortality were observed with oral administration of this extract at a superior dose of 560 mg/kg; the study's authors admitted hexane extract contamination with curcuminoids.
Limitation: Anti-inflammatory studies on isolated turmerones in humans are lacking. Most data are from cell-based assays and rodent models, and many studies used mixed turmeric oil fractions rather than pure turmerone compounds.
Evidence level: In vitro (cell lines) and animal models; no human clinical trials for isolated turmerones.
Researchers have specifically found that non-curcuminoids have a broad spectrum of anticancer activities on different cell lines including intricate and drug-resistant malignancies; although these compounds promise to exhibit similar potency as curcuminoids, their anticancer studies are still largely preclinical.
Interestingly, ar-turmerone, germacrone, and β-elemene have shown potential as anticancer agents. Yue et al. demonstrated the enhancement of antiproliferative and anti-angiogenic activities of curcumin in the presence of turmerones in human colon cancer cells and endothelial cells respectively; the superior anti-tumor effects of turmeric extract, which contains curcumin, turmerones, and other constituents, were verified in tumor-bearing mice, indicating the potential use of turmeric for colorectal cancer adjuvant therapy.
In cytotoxicity studies, some terpecurcumins showed more potent cytotoxic activities than curcumin and ar-/beta-turmerone; among them, terpecurcumin Q exhibited an IC50 of 3.9 μM against MCF-7 human breast cancer cells, with mitochondria-mediated apoptosis playing an important role in overall growth inhibition.
Limitation: All anticancer evidence for turmerones is in vitro or animal-based. The translation to human clinical outcomes has not been established. Most research to date has been conducted using cell and animal models, necessitating further clinical trials to establish their therapeutic efficacy.
Evidence level: In vitro studies; some ethnopharmacological validation.
Ar-turmerone is endowed with antimicrobial, antioxidant, and anticancer effects. Reported biological properties of the multi-component essential oils of turmeric include antifungal, mosquitocidal, antivenom, antibacterial, and antioxidant properties.
Against fungal pathogens, research published in the journal of Traditional Complementary Medicine (Apisariyakul et al., confirmed in a dedicated antidermatophytic study) demonstrated the following: Turmeric oil isolated from the turmeric rhizome possesses effective antifungal activity against dermatophytes; creams containing 3–8% w/w turmeric oil showed similar antidermatophytic activity. Ar-turmerone, the major compound in turmeric oil, showed effective antidermatophytic activity and could be used as an active marker for quality assessment of turmeric oil and as an active ingredient in antifungal products; the turmeric cream with 6% w/w turmeric oil was identified as suitable for further development as an alternative antidermatophytic preparation, with all samples showing effective activity against tested dermatophytes, especially against Trichophyton rubrum, a common dermatophyte widely spread throughout the world.
Regarding broader antifungal scope: Ar-turmerone has demonstrated in vitro antidermatophytic activity against the genera Trichophyton, Microsporum, and Epidermophyton; further clinical assessment of the antifungal properties of ar-turmerone will provide valuable insights into its molecular mechanisms of action, safety profile, and overall efficacy.
Limitation: All antimicrobial data are in vitro; no randomized controlled trials have evaluated turmerone-based preparations for clinical infections in humans.
Evidence level: In vitro, laboratory bioassay, and computational studies.
The mosquito repellent activity of C. longa essential oil was first established in 1982 by Helen Su et al., where analysis of the oil showed ar-turmerone to be the primary volatile phytochemical to exhibit mosquito repellence. Ar-turmerone has demonstrated larvicidal properties and the ability to deter biting by Aedes aegypti L. and Anopheles quadrimaculatus mosquitoes; additionally, ar-turmerone exhibits notable larvicidal activity against Culex pipiens pallens, inducing disruptions in the myofibrils of ventral muscle cells in larvae.
A 2022 computational study compared ar-turmerone to DEET. One of the phytochemicals found in abundance in C. longa essential oil, ar-turmerone, exhibits mosquito repellency comparable to synthetic DEET; molecular investigations using pharmacophore analysis revealed for the first time that ar-turmerone is a functional, structural, and pharmacophoric analogue of DEET.
Limitation: These are laboratory bioassay and computational (in silico) findings. Field efficacy and human safety for topical repellent formulations based on isolated ar-turmerone have not been evaluated in clinical trials.
Evidence level: In vitro and preclinical animal data from the early 1990s.
Antivenom activity of tumerone isolated from turmeric has been reported. The foundational work by Ferreira et al. (Toxicon, 1992) demonstrated antivenom properties for ar-turmerone. The antivenom activity of turmeric essential oil appears to be closely linked to the anti-inflammatory properties of ar-turmerone; this compound has been shown to inhibit lymphocyte proliferation and their natural killer activity. Further investigation into ar-turmerone and its pharmacological targets is described as essential to fully comprehend its potential for antivenom applications; the mechanisms by which this compound operates and its safety in humans require additional exploration.
Limitation: Antivenom data are decades old, limited to preclinical observations, and the mechanistic basis requires further characterization before any clinical conclusions can be drawn.
Evidence level: In vitro and animal studies only.
Findings indicate that curdione, germacrone, and ar-turmerone offer protective effects against chronic conditions such as insulin resistance and diabetes; however, most research to date has been conducted using cell and animal models, necessitating further clinical trials to establish their therapeutic efficacy.
Medicinal effects of turmeric essential oil in vertebrates have been reported for stroke and diabetes: a single acute dose of TEO (250–500 mg/kg oral or i.p.) was neuroprotective in rats subjected to occlusive or embolic strokes, while chronic TEO dietary supplementation (≥620 mg/kg/day) normalized serum glucose in diabetic mice. These doses, derived from murine studies, cannot be directly extrapolated to human dosing.
Ar-turmerone reduced the expression of α-glucosidase and α-amylase, supporting the hypoglycemic effect of turmeric oil hexane extract containing ar-turmerone as its primary component.
Evidence level: In vitro (human intestinal Caco-2 cell model); mechanistic relevance established, no in vivo human pharmacokinetic trials specifically for turmerones.
A mechanistically important body of work examines turmerones' capacity to influence the absorption of curcumin, which is otherwise poorly bioavailable. The rhizome of Curcuma longa is often used in Asia as a spice and as a medicine; its most well-studied component, curcumin, has been shown to exhibit poor bioavailability in animal studies and clinical trials; it was hypothesized that the presence of lipophilic components such as turmerones in turmeric extract would affect the absorption of curcumin.
The effects of turmerones on curcumin transport were evaluated in human intestinal epithelial Caco-2 cells and the roles of turmerones on P-glycoprotein (P-gp) activities and mRNA expression were evaluated; results showed that in the presence of α- and aromatic turmerones, the amount of curcumin transported into the Caco-2 cells in 2 hours was significantly increased; α-turmerone and verapamil (a P-gp inhibitor) significantly inhibited the efflux of rhodamine-123 and digoxin, i.e., inhibited the activity of P-gp.
α-Turmerone inhibited, whereas aromatic turmerone induced, P-gp activity; co-incubation of curcumin with α-turmerone, but not aromatic turmerone, increased curcumin uptake and transport through Caco-2 cells; both turmerones in combination led to intracellular curcumin accumulation but not to changes in curcumin transport; based on these observations, it was hypothesized that the administration of curcumin with turmeric oils, including turmerones, might increase its bioavailability.
The potency of inhibition by α-turmerone (50 μg/mL, approximately 229 μM) was comparable to that of the well-known P-gp inhibitor verapamil (100 μM).
Limitation: This evidence is entirely from a cell-based in vitro model. While the Caco-2 model is established as a predictor of intestinal absorption, confirmed in vivo pharmacokinetic studies in humans comparing turmerone-containing versus turmerone-free curcumin preparations have not been published as isolated turmerone intervention trials.
Evidence level: In vitro and murine models; preliminary topical cream studies.
Topical applications of aromatic turmerone (Tur) have demonstrated efficacy in alleviating skin inflammation in murine models by modulating the expression of key cytokines, presenting itself as a promising candidate for treating inflammatory skin diseases such as psoriasis. Studies reveal that turmeric creams exhibit antifungal activity and are effective against dermatophytes, confirmative of the ethnopharmacological use of this medicinal plant to treat skin diseases, especially tinea and ringworm; the 6% w/w turmeric cream was identified as suitable as an alternative antidermatophytic preparation for further development.
Evidence level: Animal (murine) studies.
A 2022 study published in Scientific Reports (PMID: 35773461) investigated the novel route of inhalation for turmerones. Turmerones are the major volatile compounds in turmeric; inhaled volatile turmerones can be transferred into the blood and organs; however, the difference between the two pathways, oral administration and inhalation, and the effect of inhaled turmerones on biological activities remained under investigation; the study compared distribution patterns of turmerones after oral administration and inhalation.
The relative levels (concentrations of turmerones in each organ/serum) in the lung, olfactory bulb, brain, heart, kidney, and epididymal fat in the inhalation group tended to be significantly higher than in the oral administration group; the relative levels in brown adipose tissue in the inhalation group were lower than in the oral administration group. These results suggest that inhaled turmerones can be incorporated into the organs of mice via different pathways from oral administration and can affect the biological function of the organs under certain conditions.
Limitation: This is entirely a murine study; no human inhalation pharmacokinetic data exist for turmerones.
Based on the published preclinical literature, turmerones are associated with effects across several body systems. The associations below represent research areas of investigation, not proven clinical benefits:
Because turmerones as isolated compounds have not reached clinical trial-stage human dosing protocols, the following dosage information is drawn exclusively from published preclinical and in vitro studies and must be understood in that context.
No standardized or consensus therapeutic dosing range for isolated turmerone compounds in humans has been established in the peer-reviewed literature as of the date of this article.
Turmeric essential oil exhibits a favorable safety profile when consumed in dietary contexts, with no documented cases of toxicity associated with its oral intake. Most research studies on turmeric oil were carried out at the preclinical level, reporting interesting pharmacological effects without associated toxicity; since TEO's safety was confirmed in healthy volunteers, the development of clinical research on TEO's active compounds remains a pending matter.
No toxicity warning has been reported for any of the components of oil extracted from the turmeric rhizome; methyl eugenol, a genotoxic carcinogen, is a constituent of turmeric leaf oil (~3%) but is not present in turmeric rhizome oil.
Based on preclinical evidence, the toxicity observed with turmeric oil intraperitoneal administration may be associated with an incomplete solvent elimination or a potential synergistic effect between curcuminoids and bisabolane-type sesquiterpenes. Possible heavy metal contamination is negligible if the oil is extracted through steam distillation (excluding mercury).
Reported cases of turmeric toxicity are frequently related to curcumin, a turmeric extract component that is not present in the oil. This distinction is important when evaluating the safety profile of turmerone-rich preparations (i.e., essential oil fractions) versus curcumin-rich extracts.
The demonstrated modulation of P-glycoprotein by turmerones carries meaningful implications for drug interactions. In the presence of α- and aromatic turmerones, the amount of curcumin transported into Caco-2 cells in 2 hours was significantly increased; α-turmerone and verapamil significantly inhibited the efflux of rhodamine-123 and digoxin, i.e., inhibited the activity of P-gp. Because digoxin is a narrow therapeutic index P-gp substrate, this in vitro finding warrants attention if turmerone-containing preparations are co-administered with P-gp substrate drugs. The anti–drug resistance capabilities of α-turmerone are proposed to be further investigated in multidrug-resistance cancer cells in which P-gp expression is significantly higher. No in vivo human pharmacokinetic drug–drug interaction studies have been published.
The larvicidal activity of ar-turmerone is mediated through an increase in detoxifying enzymes, including carboxylesterase (CarE), glutathione-S-transferase (GST), and cytochrome P450 monooxidases (P450); long-term studies are described as essential to elucidate the specificity of ar-turmerone's insecticidal action and to objectively assess its safety for both the environment and human health.
In Europe, turmeric and its essential oil have been listed among botanicals allowed to be used in food supplements. This status applies to the whole turmeric plant and its essential oil preparations, not to isolated turmerone fractions specifically.
Systematic toxicological profiling of isolated turmerones in humans is absent from the literature. Future studies should focus on prolonged intervention periods and specific endpoints for evaluating health outcomes to comprehensively assess the long-term safety and efficacy of these turmeric essential oil compounds. The absence of documented toxicity in dietary use contexts, combined with the route-dependent findings in animal studies, suggests that oral intake via food or essential oil formulations is considerably safer than parenteral (intraperitoneal) routes at high doses—but this inference is drawn from preclinical data only.
Health conditions that Tumerone may help support.
Body systems that Tumerone may help support.
Go back